Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04446858

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in Patients With and Without TIPS With ACLF, Renal Failure and Hepatorenal Syndrome

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
University Hospital, Bonn · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (TIPS). Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

Detailed description

NECTAR consists of patients with ACLF and renal failure with and without receiving transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Internal Medicine I, University of Bonn, Germany and receiving a structured routine evaluation and follow up program. The diagnosis of cirrhosis was based on clinical, hemodynamic and biochemical parameters, and ultrasound and/or biopsy criteria.

Conditions

Timeline

Start date
2021-01-01
Primary completion
2030-07-01
Completion
2030-07-01
First posted
2020-06-25
Last updated
2022-05-18

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04446858. Inclusion in this directory is not an endorsement.